硼替佐米、地塞米松联合来那度胺化疗治疗多发性骨髓瘤患者的效果  

Effect of Bortezomib,Dexamethasone Combined with Lenalidomide in the Treatment of Multiple Myeloma Patients

作　　者：林一凤 马小美 LIN Yifeng;MA Xiaomei(Longyan First Hospital Affiliated to Fujian Medical University,Longyan 364000,China;不详)

机构地区：[1]福建医科大学附属龙岩第一医院,福建龙岩364000

出　　处：《中外医学研究》2025年第10期24-27,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨硼替佐米、地塞米松联合来那度胺化疗治疗多发性骨髓瘤患者的效果。方法:回顾性选取2021年9月—2024年1月福建医科大学附属龙岩第一医院收治的96例多发性骨髓瘤患者作为研究对象,依据治疗方案不同分为对照组(硼替佐米、地塞米松联合治疗)与观察组(在对照组基础上联合来那度胺治疗),各48例。两组治疗效果、生化指标、免疫功能情况和炎症反应指标。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);观察组治疗后骨髓浆细胞比例、单克隆蛋白、β2-微球蛋白、CD8^(+)、C反应蛋白、白细胞介素-6、肿瘤坏死因子-α水平低于对照组,CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平高于对照组,差异有统计学意义(P<0.05)。结论:多发性骨髓瘤患者联合使用硼替佐米、地塞米松和来那度胺,可提高临床治疗效果,调节免疫功能,降低生化指标和炎症反应指标。Objective:To investigate the effect of Bortezomib,Dexamethasone combined with Lenalidomide in the treatment of multiple myeloma patients.Method:A total of 96 patients with multiple myeloma who admitted to Longyan First Hospital Affiliated to Fujian Medical University from September 2021 to January 2024 were retrospectively selected as the research objects,they were divided into the control group(Bortezomib and Dexamethasone combined treatment)and the observation group(Lenalidomide combined treatment on the basis of the control group)according to different treatment schemes,with 48 cases in each group.The therapeutic effect,biochemical indexes,immune function and inflammatory response indexes of two groups were compared.Result:The total effective rate of the observation group was higher than that of the control group,and the difference was significant(P<0.05);after treatment,the bone marrow plasma cells proportion,monoclonal protein,β2-microglobulin,CD8^(+),C-reactive protein,interleukin-6 and tumor necrosis factor-αlevels in the observation group were lower than those in the control group,and the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were higher than those in the control group,the differences were significant(P<0.05).Conclusion:The combined use of Bortezomib,Dexamethasone and Lenalidomide in patients with multiple myeloma can improve the clinical treatment effect,regulate immune function,and reduce biochemical indicators and inflammatory response indicators.

关 键 词：硼替佐米 地塞米松 来那度胺 多发性骨髓瘤 生化指标 免疫功能 炎症反应 

分 类 号：R733.3[医药卫生—肿瘤]